磺胺氯吡嗪钠中药复方对小鼠体内抗弓形虫疗效的观察

Treatment Effects of Sulfachloropyrazine-sodium with Scutellaria Baicalensis and Glycyrrhiza against Acute Murine Toxoplasmosis

为探索治疗动物弓形虫病的有效药物组方,本研究以磺胺嘧啶钠作为对照首先通过药物体外试验观察磺胺氯吡嗪钠、甘草和黄芩抑制弓形虫增殖的效果,然后分别用磺胺氯吡嗪钠、甘草和黄芩以及3种药物的复方制剂,对人工感染弓形虫RH株的KM小鼠进行体内治疗试验。体外试验表明磺胺氯吡嗪钠、磺胺嘧啶钠、黄芩和甘草对弓形虫速殖子均有一定的抑制效果,磺胺氯吡嗪钠抑制效果最好。小鼠体内试验表明单独使用磺胺嘧啶钠、甘草和黄芩均可不同程度地延长小鼠存活时间,但均不能避免小鼠死亡,而单独使用磺胺氯吡嗪钠可使小鼠的存活率达到40%,在同等剂量下,磺胺氯吡嗪钠与黄芩和甘草配伍后,疗效得到明显提高,可显著延长小鼠存活时间,并使小鼠存活率高达50%。本研究的结果提示磺胺氯吡嗪钠具有显著体内抗弓形虫的作用,与甘草和黄芩配伍后的中西药复方制剂,能在保持疗效的基础上显著减少磺胺氯吡嗪钠的用量,因此磺胺氯吡嗪钠、甘草和黄芩复方制剂是未来治疗动物弓形虫病的优良方案之一。

The objective of this study was to screen effective prescription of chemical drug and Chinese herbal medicines against Toxoplasmosis. First, the inhibiting effects of sulfachloropy- razine-sodium （SPZ）, sulfadiazine-sodium （SD）, scutellariae and glycyrrhizae against Toxoplama gondii （T. gondii） were observed on the Ana-1 cells in vitro. Then mice infected intraperitone- ally with tachyzoites of T. gondii were treated separately with each drug and a prescription of SPZ combined with scutellariae and glycyrrhiza on mouse model in vivo. Our results indicated that each of the four drugs could significantly inhibit the proliferation of T. gondii in vitro and could prolong the time of death in mice infected with T. gondii, but Glycyrrhizae, Scutellariae or SD used alone could not protect these mice from death. Mice treated with SPZ alone could have a survival rate of 40 %, while SPZ combined with Glycyrrhizae and Scutellariae, the survival rate of mice could be up to 50X and the abdominal cavity of the mice were tachyzoite-free. The results ofthis study suggest that SPZ have significant role in vitro and in vivo anti-T, gondii, while SPZ was applied with Chinese medicine-Glycyrrhizae and Scutellariae, not only the therapeutic effects could be improved, but also the dose of chemotherapy could be lower to reducing the toxicity of drugs. It can be concluded that the compound of SPZ, Glycyrrhizae andScutellariae will be a bet- ter choice against animal Toxoplasmosis in the future.